Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Long-Term Investments (2020 - 2026)

Nautilus Biotechnology has reported Long-Term Investments over the past 7 years, most recently at $47.5 million for Q1 2026.

  • Quarterly results put Long-Term Investments at $47.5 million for Q1 2026, down 12.07% from a year ago — trailing twelve months through Mar 2026 was $47.5 million (down 12.07% YoY), and the annual figure for FY2025 was $52.7 million, down 30.97%.
  • Long-Term Investments reached $47.5 million in Q1 2026 per NAUT's latest filing, down from $52.7 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $134.6 million in Q1 2023 and bottomed at $24.9 million in Q1 2022.
  • Median Long-Term Investments over the past 5 years was $65.7 million (2022), compared with a mean of $71.1 million.
  • Peak annual rise in Long-Term Investments hit 689.01% in 2022, while the deepest fall reached 83.34% in 2022.
  • Over 5 years, Long-Term Investments stood at $129.2 million in 2022, then dropped by 29.82% to $90.6 million in 2023, then decreased by 15.71% to $76.4 million in 2024, then tumbled by 30.97% to $52.7 million in 2025, then fell by 9.92% to $47.5 million in 2026.
  • Business Quant data shows Long-Term Investments for NAUT at $47.5 million in Q1 2026, $52.7 million in Q4 2025, and $37.1 million in Q3 2025.